Novo Nordisk, obesity

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.
Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...